Literature DB >> 8528294

Surgery in rhabdomyosarcoma of the bladder, prostate and vagina.

M Fisch1, R Bürger, U Barthels, P Gutjahr, R Hohenfellner.   

Abstract

The treatment of bladder and prostate rhabdomyosarcoma (RMS) is highly controversial. Aside from chemotherapy, treatment modalities include conservative surgery, radical surgery, and pre-, intra-, or postoperative irradiation. Between 1968 and 1993, 78 children with RMS were treated at our institution. In all, 22 tumors were located in the urogenital tract (bladder/prostate, 13; paratesticular, 5; vaginal, 2; others, 2). Altogether, 6 patients had stage II disease; 7, stage III disease; and 2, stage IV disease. All 15 patients with RMS of the bladder, prostate, or vagina received chemotherapy, and 4 had additional radiotherapy. Surgery was also done in 10 patients; parents refused an operation in 3 cases. In all, 3 patients in an advanced tumor stage died of their disease. All other children currently show no evidence of disease (mean follow-up, 6 years; range, from 2 months to 18 years). After chemotherapy, radical operative intervention with multiple biopsies (encircling the tumor)--in contrast to local tumor excision or partial resection--permits complete tumor resection followed by excellent long-term results. Following radiotherapy, often a consequence of organ-sparing therapy, many complications ensued (60%); therefore, irradiation should be restricted to highly selected cases.

Entities:  

Mesh:

Year:  1995        PMID: 8528294     DOI: 10.1007/bf00182965

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  28 in total

1.  Long-term sequelae of conservative treatment by surgery, brachytherapy, and chemotherapy for vulval and vaginal rhabdomyosarcoma in children.

Authors:  F Flamant; A Gerbaulet; C Nihoul-Fekete; D Valteau-Couanet; D Chassagne; J Lemerle
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  Proceedings: Surgery of bladder and prostatic neoplasms in children.

Authors:  H W Clatworth; V Braren; J P Smith
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

3.  Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma of the bladder, prostate, vagina, uterus, and cervix. A comparison of the results in Intergroup Rhabdomyosarcoma Studies I and II.

Authors:  R B Raney; E A Gehan; D M Hays; M Tefft; W A Newton; V Haeberlen; H M Maurer
Journal:  Cancer       Date:  1990-11-15       Impact factor: 6.860

4.  Partial cystectomy in the management of rhabdomyosarcoma of the bladder: a report from the Intergroup Rhabdomyosarcoma Study.

Authors:  D M Hays; W Lawrence; W M Crist; E Wiener; R B Raney; A Ragab; M Tefft; B Webber; J Johnston; H M Maurer
Journal:  J Pediatr Surg       Date:  1990-07       Impact factor: 2.545

5.  Primary site as a prognostic variable for children with pelvic soft tissue sarcomas.

Authors:  B Raney; A Carey; H M Snyder; J W Duckett; L Schnaufer; H K Rosenberg; S Mahboubi; J Chatten; P Littman
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

6.  The Intergroup Rhabdomyosarcoma Study-I. A final report.

Authors:  H M Maurer; M Beltangady; E A Gehan; W Crist; D Hammond; D M Hays; R Heyn; W Lawrence; W Newton; J Ortega
Journal:  Cancer       Date:  1988-01-15       Impact factor: 6.860

7.  Genitourinary rhabdomyosarcoma.

Authors:  W E Kaplan; C F Firlit; R M Berger
Journal:  J Urol       Date:  1983-07       Impact factor: 7.450

8.  Rhabdomyosarcoma in infants and children: factors affecting long-term survival.

Authors:  F E Ehrlich; J E Haas; W B Kiesewetter
Journal:  J Pediatr Surg       Date:  1971-10       Impact factor: 2.545

9.  The Mainz pouch II (sigma rectum pouch).

Authors:  M Fisch; R Wammack; S C Müller; R Hohenfellner
Journal:  J Urol       Date:  1993-02       Impact factor: 7.450

10.  The Mainz pouch (mixed augmentation ileum and cecum) for bladder augmentation and continent diversion.

Authors:  J W Thüroff; P Alken; H Riedmiller; U Engelmann; G H Jacobi; R Hohenfellner
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.